AWTTC nominated for Moondance Cancer Award

12 July 2024

The All Wales Therapeutics and Toxicology Centre (AWTTC) was thrilled that the One Wales Medicines (OW) process was shortlisted for a prestigious Moondance Cancer Award.

The Moondance Cancer Awards, Wales’ only dedicated Cancer awards, celebrate and spotlight individuals and teams across NHS Wales and its partners who deliver, lead and innovate cancer services.

The AWTTC OW process assesses medicines that are not routinely available in Wales for specific groups of patients whose clinical need isn’t met by available treatments. After consideration of the evidence, a recommendation is made on whether to make the medicine available for all patients who meet the treatment criteria. Around half of all OW recommendations are for cancer medicines and patients in Wales have been among the first in the world to have routine access to dostarlimab to treat a type of rectal cancer and, in the UK, to abiraterone for a type of prostate cancer.

The OW process was shortlisted for the Working Together Achievement Award in recognition that AWTTC works with clinicians and patient groups to identify and assess suitable medicines for the treatment of cancer.

Colleagues from AWTTC who work on the OW process attended the celebration and awards night on 13 June at Depot in Cardiff. Although the overall winner was a very deserving team from Swansea Bay UHB, AWTTC was delighted to be shortlisted especially considering that over 100 nominations were submitted.

More about the Moondance Cancer Initiative including a list of Award winners can be found on their website at: https://moondance-cancer.wales/awards

More about the AWTTC One Wales Medicines process is available at: https://awttc.nhs.wales/one-wales